vs
FiscalNote Holdings, Inc.（NOTE）与Intellia Therapeutics, Inc.（NTLA）财务数据对比。点击上方公司名可切换其他公司
Intellia Therapeutics, Inc.的季度营收约是FiscalNote Holdings, Inc.的1.0倍（$23.0M vs $22.2M），Intellia Therapeutics, Inc.同比增速更快（78.8% vs -24.7%），FiscalNote Holdings, Inc.自由现金流更多（$-1.9M vs $-69.4M），过去两年Intellia Therapeutics, Inc.的营收复合增速更高（-10.8% vs -16.8%）
FiscalNote Holdings, Inc.（常称FiscalNote）是一家上市的软件数据与传媒企业，总部位于美国华盛顿特区，2013年由三位创始人创立。核心业务为通过政府关系管理服务FiscalNote GRM提供软件工具、平台、数据服务与资讯，同时依托人工智能平台分析美国待审议法案相关内容。
Intellia Therapeutics是美国临床阶段生物技术企业，专注于依托CRISPR技术开发具有潜在治愈效果的创新疗法。公司体内项目采用静脉注射CRISPR疗法，通过专属递送技术可在特定靶组织内精准编辑致病基因；体外项目则利用CRISPR改造细胞制备治疗产品，主攻未被满足的医疗需求。
NOTE vs NTLA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.2M | $23.0M |
| 净利润 | — | $-95.8M |
| 毛利率 | — | — |
| 营业利润率 | -83.7% | -428.9% |
| 净利率 | — | -416.2% |
| 营收同比 | -24.7% | 78.8% |
| 净利润同比 | — | 25.7% |
| 每股收益（稀释后） | $-2.81 | $-0.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $22.2M | $23.0M | ||
| Q3 25 | $22.4M | $13.8M | ||
| Q2 25 | $23.3M | $14.2M | ||
| Q1 25 | $27.5M | $16.6M | ||
| Q4 24 | $29.5M | $12.9M | ||
| Q3 24 | $29.4M | $9.1M | ||
| Q2 24 | $29.2M | $7.0M | ||
| Q1 24 | $32.1M | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | $-24.9M | $-101.3M | ||
| Q2 25 | $-13.3M | $-101.3M | ||
| Q1 25 | $-4.3M | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $-14.9M | $-135.7M | ||
| Q2 24 | $-12.8M | $-147.0M | ||
| Q1 24 | $50.6M | $-107.4M |
| Q4 25 | -83.7% | -428.9% | ||
| Q3 25 | -43.4% | -808.9% | ||
| Q2 25 | -31.9% | -772.2% | ||
| Q1 25 | -50.0% | -726.6% | ||
| Q4 24 | -19.4% | -1059.9% | ||
| Q3 24 | -23.1% | -1589.0% | ||
| Q2 24 | -27.2% | -1998.6% | ||
| Q1 24 | -35.6% | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | -110.8% | -735.2% | ||
| Q2 25 | -57.0% | -710.8% | ||
| Q1 25 | -15.4% | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | -50.7% | -1489.5% | ||
| Q2 24 | -43.6% | -2112.6% | ||
| Q1 24 | 157.6% | -371.3% |
| Q4 25 | $-2.81 | $-0.81 | ||
| Q3 25 | $-1.73 | $-0.92 | ||
| Q2 25 | $-0.08 | $-0.98 | ||
| Q1 25 | $-0.03 | $-1.10 | ||
| Q4 24 | $1.88 | $-1.27 | ||
| Q3 24 | $-1.33 | $-1.34 | ||
| Q2 24 | $-0.09 | $-1.52 | ||
| Q1 24 | $0.37 | $-1.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.3M | $449.9M |
| 总债务越低越好 | $128.4M | — |
| 股东权益账面价值 | $62.0M | $671.4M |
| 总资产 | $255.1M | $842.1M |
| 负债/权益比越低杠杆越低 | 2.07× | — |
8季度趋势，按日历期对齐
| Q4 25 | $26.3M | $449.9M | ||
| Q3 25 | $31.2M | $511.0M | ||
| Q2 25 | $38.5M | $459.7M | ||
| Q1 25 | $46.3M | $503.7M | ||
| Q4 24 | $34.6M | $601.5M | ||
| Q3 24 | $32.7M | $658.1M | ||
| Q2 24 | $37.7M | $691.1M | ||
| Q1 24 | $43.6M | $791.3M |
| Q4 25 | $128.4M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $116.7M | — | ||
| Q1 25 | $118.0M | — | ||
| Q4 24 | $147.1M | — | ||
| Q3 24 | $152.2M | — | ||
| Q2 24 | $145.9M | — | ||
| Q1 24 | $153.0M | — |
| Q4 25 | $62.0M | $671.4M | ||
| Q3 25 | $75.5M | $748.4M | ||
| Q2 25 | $95.1M | $715.3M | ||
| Q1 25 | $98.7M | $779.9M | ||
| Q4 24 | $97.8M | $872.0M | ||
| Q3 24 | $98.5M | $962.6M | ||
| Q2 24 | $106.9M | $971.1M | ||
| Q1 24 | $106.1M | $1.0B |
| Q4 25 | $255.1M | $842.1M | ||
| Q3 25 | $273.9M | $925.3M | ||
| Q2 25 | $288.3M | $898.9M | ||
| Q1 25 | $299.7M | $986.2M | ||
| Q4 24 | $326.2M | $1.2B | ||
| Q3 24 | $337.9M | $1.2B | ||
| Q2 24 | $346.3M | $1.2B | ||
| Q1 24 | $357.8M | $1.3B |
| Q4 25 | 2.07× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 1.50× | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-279.0K | $-69.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.9M | $-69.4M |
| 自由现金流率自由现金流/营收 | -8.7% | -301.6% |
| 资本支出强度资本支出/营收 | 7.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.6M | $-395.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-279.0K | $-69.3M | ||
| Q3 25 | $-8.3M | $-76.9M | ||
| Q2 25 | $-6.2M | $-99.6M | ||
| Q1 25 | $3.3M | $-148.9M | ||
| Q4 24 | $-1.3M | $-85.2M | ||
| Q3 24 | $-3.0M | $-84.8M | ||
| Q2 24 | $-3.7M | $-58.2M | ||
| Q1 24 | $2.7M | $-120.7M |
| Q4 25 | $-1.9M | $-69.4M | ||
| Q3 25 | $-10.4M | $-76.9M | ||
| Q2 25 | $-7.7M | $-99.9M | ||
| Q1 25 | $1.3M | $-149.7M | ||
| Q4 24 | $-3.4M | $-86.2M | ||
| Q3 24 | $-5.4M | $-86.1M | ||
| Q2 24 | $-6.5M | $-59.2M | ||
| Q1 24 | $1.0M | $-123.2M |
| Q4 25 | -8.7% | -301.6% | ||
| Q3 25 | -46.2% | -558.2% | ||
| Q2 25 | -33.0% | -701.0% | ||
| Q1 25 | 4.7% | -900.1% | ||
| Q4 24 | -11.4% | -669.4% | ||
| Q3 24 | -18.4% | -945.2% | ||
| Q2 24 | -22.1% | -850.9% | ||
| Q1 24 | 3.3% | -425.7% |
| Q4 25 | 7.4% | 0.5% | ||
| Q3 25 | 9.3% | 0.2% | ||
| Q2 25 | 6.4% | 1.7% | ||
| Q1 25 | 7.2% | 4.4% | ||
| Q4 24 | 6.8% | 7.6% | ||
| Q3 24 | 8.3% | 14.0% | ||
| Q2 24 | 9.4% | 14.5% | ||
| Q1 24 | 5.3% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOTE
| Subscription | $21.2M | 95% |
| Advisory Advertising And Other | $1.0M | 5% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
